Mechanisms and models in heart failure: the biomechanical model and beyond.
暂无分享,去创建一个
[1] N. Hollenberg,et al. Literature alert , 2002 .
[2] H. Sabbah. The cardiac support device and the myosplint: treating heart failure by targeting left ventricular size and shape. , 2003, The Annals of thoracic surgery.
[3] H Harasaki,et al. Structural and left ventricular histologic changes after implantable LVAD insertion. , 1995, The Annals of thoracic surgery.
[4] M. Packer,et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. , 1984, The New England journal of medicine.
[5] S. Kardia,et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. , 2002, The New England journal of medicine.
[6] M C Oz,et al. Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. , 1995, Circulation.
[7] P. Doevendans,et al. Stem cell therapy for ischemic heart disease. , 2003, Trends in molecular medicine.
[8] M. Quiñones,et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. , 1995, Circulation.
[9] Y. Hirota,et al. [The natural history of dilated cardiomyopathy and pathophysiology of congestive heart failure]. , 1986, Journal of cardiography. Supplement.
[10] B. Pitt,et al. Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .
[11] E. Foster,et al. Effects of Long-Term Biventricular Stimulation for Resynchronization on Echocardiographic Measures of Remodeling , 2002, Circulation.
[12] J. Cleland,et al. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure , 2004, Expert review of cardiovascular therapy.
[13] M. Bristow,et al. Inotropes and β-blockers: Is there a need for new guidelines? , 2001 .
[14] D. Mann,et al. Cardiocyte contractile performance in experimental biventricular volume-overload hypertrophy. , 1993, The American journal of physiology.
[15] Chu-Pak Lau,et al. Tissue Doppler Echocardiographic Evidence of Reverse Remodeling and Improved Synchronicity by Simultaneously Delaying Regional Contraction After Biventricular Pacing Therapy in Heart Failure , 2002, Circulation.
[16] A. Feldman,et al. Downregulation of Matrix Metalloproteinases and Reduction in Collagen Damage in the Failing Human Heart After Support With Left Ventricular Assist Devices , 2001, Circulation.
[17] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[18] S. Tyagi,et al. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts , 1996, Molecular and Cellular Biochemistry.
[19] S. Houser,et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. , 1998, Circulation.
[20] J. Ross. Mechanisms of cardiac contraction. What roles for preload, afterload and inotropic state in heart failure? , 1983, European heart journal.
[21] Y. Sun,et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.
[22] H. Ikram,et al. DOUBLE-BLIND TRIAL OF CHRONIC ORAL BETA BLOCKADE IN CONGESTIVE CARDIOMYOPATHY , 1981, The Lancet.
[23] H. Sabbah,et al. Reversal of Chronic Molecular and Cellular Abnormalities Due to Heart Failure by Passive Mechanical Ventricular Containment , 2003, Circulation research.
[24] Q. Li,et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. , 1998, The Journal of clinical investigation.
[25] S. Kardia,et al. Synergistic Polymorphisms of β1- and α2C-Adrenergic Receptors and the Risk of Congestive Heart Failure , 2002 .
[26] A. Nitenberg,et al. Coronary vasodilation induced by intracoronary enalaprilat: an argument for the role of a local renin-angiotensin system in patients with dilated cardiomyopathy. , 1989, European heart journal.
[27] J. Chrast,et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. , 2004, The Journal of clinical investigation.
[28] M. Bristow. β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .
[29] D. DeMets,et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.
[30] D. Levy,et al. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. , 1997, The New England journal of medicine.
[31] A. Quyyumi,et al. Cardiac sympathetic nerve function in congestive heart failure. , 1996, Circulation.
[32] G. Reeder. Heart Disease: A Textbook of Cardiovascular Medicine , 1984 .
[33] N Reichek,et al. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. , 1989, Journal of the American College of Cardiology.
[34] R. Doughty,et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease , 1997 .
[35] S. Vatner. Reduced subendocardial myocardial perfusion as one mechanism for congestive heart failure. , 1988, The American journal of cardiology.
[36] B. Groves,et al. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. , 1997, The Journal of clinical investigation.
[37] B. Pau,et al. Circulating cardiac troponin I in severe congestive heart failure. , 1997, Circulation.
[38] S. Kumar,et al. Differential gene expression of extracellular matrix components in dilated cardiomyopathy , 1996, Journal of cellular biochemistry.
[39] D. Pimentel,et al. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. , 1998, Circulation.
[40] H. Matsubara. Risk to the coronary arteries of intracoronary stem cell infusion and G-CSF cytokine therapy , 2004, The Lancet.
[41] H. Meiselman,et al. Mean red cell volume as a correlate of blood pressure. , 1996, Circulation.
[42] Richard J. Jones. Heart Disease: A Textbook of Cardiovascular Medicine , 1980 .
[43] J. Cohn. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. , 1995, Circulation.
[44] D. Brutsaert,et al. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. , 2002, Circulation.
[45] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[46] B. Kobilka,et al. Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission , 1999, Nature.
[47] L. Leinwand,et al. Myosin heavy chain gene expression in human heart failure. , 1997, The Journal of clinical investigation.
[48] W. Kiowski,et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. , 1997, Circulation research.
[49] E. Braunwald. Heart Disease: A Textbook of Cardiovascular Medicine , 1992, Annals of Internal Medicine.
[50] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[51] Vincent Dor,et al. The Endoventricular Circular Patch Plasty (“Dor Procedure”) in Ischemic Akinetic Dilated Ventricles , 2001, Heart Failure Reviews.
[52] M. Bristow,et al. Inotropes and beta-blockers: is there a need for new guidelines? , 2001, Journal of cardiac failure.
[53] M. Bristow,et al. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. , 1996, Circulation.
[54] R. Virmani,et al. Apoptosis in myocytes in end-stage heart failure. , 1996, The New England journal of medicine.
[55] E Erdmann,et al. Intracellular Calcium Handling in Isolated Ventricular Myocytes From Patients With Terminal Heart Failure , 1992, Circulation.
[56] M. Raynolds,et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. , 2000, Journal of molecular and cellular cardiology.
[57] J. Towbin,et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy , 2002, The Lancet.
[58] S. Vatner,et al. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure. , 1993, The American journal of physiology.
[59] D. Mann,et al. Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.
[60] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[61] K. Adams,et al. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? , 2003, Journal of cardiac failure.
[62] Bernd Westphal,et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration , 2003, The Lancet.
[63] D. Delurgio,et al. Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart Failure , 2003, Circulation.
[64] D C Harrison,et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.
[65] Michael D. Schneider,et al. Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[66] P. Korner,et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. , 1986, Circulation.
[67] K. Weber,et al. Structural remodeling in hypertensive heart disease and the role of hormones. , 1994, Hypertension.
[68] J. Bergsland,et al. Partial left ventriculectomy to treat end-stage heart disease. , 1997, The Annals of thoracic surgery.
[69] B. Massie. 15 years of heart-failure trials: what have we learned? , 1998, The Lancet.
[70] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[71] Gregory S. Nelson,et al. Left Ventricular or Biventricular Pacing Improves Cardiac Function at Diminished Energy Cost in Patients With Dilated Cardiomyopathy and Left Bundle-Branch Block , 2000, Circulation.
[72] C A Beltrami,et al. Apoptosis in the failing human heart. , 1997, The New England journal of medicine.
[73] Federica Limana,et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[74] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[75] J. Schaper,et al. Cardiomyocyte apoptosis in acute and chronic conditions , 1998, Basic Research in Cardiology.
[76] G. Dorn,et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure , 2003, Nature Medicine.
[77] M. Pfeffer,et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.
[78] M. Domanski,et al. Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the &bgr;-Blocker Evaluation of Survival Trial , 2004, Circulation.
[79] A J LINZBACH,et al. Heart failure from the point of view of quantitative anatomy. , 1960, The American journal of cardiology.
[80] J. Holmes,et al. Impaired subendocardial function in tachycardia-induced cardiac failure. , 1995, The American journal of physiology.
[81] D. Zechner,et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. , 1996, The Journal of clinical investigation.
[82] M. Pfeffer,et al. Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) , 2003, European journal of heart failure.
[83] F. Spinale,et al. Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy , 1998 .
[84] L. Stevenson,et al. Medical management of advanced heart failure. , 2002, JAMA.
[85] Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) , 2002 .
[86] G. Dorn,et al. Interactions Between Phospholamban and &bgr;-Adrenergic Drive May Lead to Cardiomyopathy and Early Mortality , 2001, Circulation.
[87] F. Clubb,et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.
[88] K. Swedberg,et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.
[89] H Harasaki,et al. Left ventricular echocardiographic and histologic changes: impact of chronic unloading by an implantable ventricular assist device. , 1996, Journal of the American College of Cardiology.
[90] B. Parsons,et al. Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.
[91] J Ross,et al. Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy. , 1985, Journal of the American College of Cardiology.
[92] M. Bristow. What Type of β-Blocker Should Be Used to Treat Chronic Heart Failure? , 2000 .
[93] F. Tristani,et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.
[94] Jacques Melin,et al. Cardiac Mechanics During Development of Heart-failure , 1993 .
[95] James T. Willerson,et al. Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure , 2003, Circulation.
[96] M. Acker,et al. Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. , 2004, Journal of cardiac failure.
[97] B. Fleischmann,et al. Bone marrow–derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation , 2004, Nature Medicine.
[98] R. Walsh,et al. Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. , 1995, The Journal of clinical investigation.
[99] B. Carabello,et al. Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. , 1994, The Journal of clinical investigation.
[100] Won Yong Kim,et al. Impact of Acute Biventricular Pacing on Left Ventricular Performance and Volumes in Patients with Severe Heart Failure , 2001, Cardiology.
[101] D. Kass,et al. Stabilization of chronic remodeling by asynchronous cardiomyoplasty in dilated cardiomyopathy: effects of a conditioned muscle wrap. , 1997, Circulation.
[102] A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001 .
[103] J. Cohn,et al. Prognostic Significance of Serial Changes in Left Ventricular Ejection Fraction in Patients With Congestive Heart Failure , 1993, Circulation.
[104] M. Lohse,et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[105] B. Nico,et al. Right ventricular dysplasia: an ultrastructural study. , 1989, European heart journal.
[106] J. S. Janicki,et al. Cardiac myocyte necrosis induced by angiotensin II. , 1991, Circulation research.
[107] M. Packer. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.
[108] C H Davies,et al. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. , 1995, Circulation.
[109] R. Quaife,et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.
[110] T. R. I. Nvestigators. A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .
[111] S. Bolling,et al. Early outcome of mitral valve reconstruction in patients with end-stage cardiomyopathy. , 1995, The Journal of thoracic and cardiovascular surgery.
[112] B. Bozkurt,et al. New therapeutics for chronic heart failure. , 2002, Annual review of medicine.
[113] J. Federman,et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. , 1984, Journal of the American College of Cardiology.
[114] F. Beyersdorf,et al. Endoventrikuläre Patchplastik bei Patienten mit idiopathischer, dilatativer Kardiomyopathie – eine Alternative zur Herztransplantation? , 2001, Zeitschrift für Kardiologie.
[115] Hyun-Jai Cho,et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial , 2004, The Lancet.
[116] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[117] O. Hess,et al. Left ventricular function and myocardial structure in aortic valve disease before and after surgery. , 1984, Herz.
[118] J. S. Janicki,et al. Myocardial fibrosis: functional significance and regulatory factors. , 1993, Cardiovascular research.
[119] W. Grossman,et al. Evaluation and Management of Diastolic Heart Failure , 2003, Circulation.
[120] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[121] M. Bristow. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. , 2003, Circulation.
[122] P. Grayburn,et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. , 1995, Journal of the American College of Cardiology.
[123] D. Burkhoff,et al. Chronic Unloading by Left Ventricular Assist Device Reverses Contractile Dysfunction and Alters Gene Expression in End-Stage Heart Failure , 2000, Circulation.
[124] A. Friedl,et al. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. , 1991, Circulation.
[125] N. Hollenberg,et al. Relation of the Renin‐Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure , 1981, Circulation.
[126] O. Hess,et al. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. , 1993, Journal of the American College of Cardiology.
[127] F. Leclercq,et al. Heart rate as a determinant of L-type Ca2+ channel activity: Mechanisms and implication in force-frequency relation , 1998, Basic Research in Cardiology.
[128] Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. , 1994, Circulation.
[129] Angelo Auricchio,et al. Cardiac resynchronization therapy in heart failure. , 2005, Italian heart journal : official journal of the Italian Federation of Cardiology.
[130] P. Wernet,et al. Repair of Infarcted Myocardium by Autologous Intracoronary Mononuclear Bone Marrow Cell Transplantation in Humans , 2002, Circulation.
[131] D. Brutsaert,et al. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. , 2002, Circulation.
[132] G. Jennings,et al. Adrenergic nervous system in heart failure. , 1997, The American journal of cardiology.
[133] S. Goldstein,et al. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. , 1992, Journal of the American College of Cardiology.
[134] S. Stephen. Unwanted effects of propranolol. , 1966, The American journal of cardiology.
[135] David A. Williams,et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts , 2004, Nature.
[136] John W. Adams,et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[137] K. Adams,et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.
[138] M. Domanski,et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. , 2003, Journal of cardiac failure.
[139] E. Sonnenblick,et al. Stretch-induced programmed myocyte cell death. , 1995, The Journal of clinical investigation.
[140] K. Weber,et al. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. , 1997, Circulation.
[141] D. DeMets,et al. Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.
[142] S. Chugh,et al. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. , 1997, Circulation.